Neurometabolic effects of ACTH on free amino compounds in opsoclonus-myoclonus syndrome.
To evaluate the possible role of central free amino compounds in pediatric opsoclonus-myoclonus syndrome (OMS), 21 cerebrospinal fluid (CSF) amino compounds were measured by an amino acid analyzer or mass spectroscopy in 74 anesthetized children, 54 with OMS and 20 age-matched neurological controls. In OMS, only phosphoethanolamine was increased compared to controls; OMS severity and duration had significant converse effects on alanine and phosphoethanolamine. In contrast, corticotropin (ACTH) treatment was associated with increased alanine and phenylalanine, and decreased taurine compared to controls and untreated OMS, and increased glutamine, lysine, ornithine, and tyrosine compared to untreated OMS. Other than low taurine, these effects were not found with corticosteroid treatment, and non-steroidogenic immunotherapy had no effect. The ACTH dose-association was most apparent for alanine and phosphoethanolamine, but lysine and ornithine were also higher in the high-dose ACTH group. There were no significant disease- or treatment-associated perturbations in GABA, glycine, or other amino acids. These data suggest a unique pattern of ACTH effects on non-neurotransmitter CSF amino compounds, for the most part not shared by steroids.
Pranzatelli
M R
MR
Department of Neurology, Division of Child and Adolescent Neurology, Southern Illinois University School of Medicine, Springfield, Illinois, USA. mpranzatelli@siumed.edu
Tate
E D
ED
Crowley
J M
JM
Toennies
B
B
Creer
M
M
D000324:Adrenocorticotropic Hormone / Q000494:pharmacology / Q000627:therapeutic use*; D000409:Alanine / Q000134:cerebrospinal fluid / Q000378:metabolism; D000596:Amino Acids / Q000134:cerebrospinal fluid* / Q000378:metabolism; D000704:Analysis of Variance; D002648:Child; D002675:Child, Preschool; D002849:Chromatography, Gas / Q000379:methods; D003345:Corticosterone / Q000494:pharmacology / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005260:Female; D005973:Glutamine / Q000134:cerebrospinal fluid / Q000378:metabolism; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008239:Lysine / Q000134:cerebrospinal fluid / Q000378:metabolism; D008297:Male; D013058:Mass Spectrometry / Q000379:methods; D053578:Opsoclonus-Myoclonus Syndrome / Q000134:cerebrospinal fluid / Q000188:drug therapy* / Q000378:metabolism; D009952:Ornithine / Q000134:cerebrospinal fluid / Q000378:metabolism; D010649:Phenylalanine / Q000134:cerebrospinal fluid / Q000378:metabolism; D012720:Severity of Illness Index; D013654:Taurine / Q000134:cerebrospinal fluid / Q000378:metabolism; D014443:Tyrosine / Q000134:cerebrospinal fluid / Q000378:metabolism
D000596:Amino Acids; D005973:Glutamine; D013654:Taurine; D014443:Tyrosine; D010649:Phenylalanine; D000324:Adrenocorticotropic Hormone; D009952:Ornithine; D008239:Lysine; D000409:Alanine; D003345:Corticosterone